SCHEMBL26081047

SCHEMBL26081047

N#Cc1ccc(CC2(F)CCCCC2)c(F)c1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RORC P51449 2/20 0.39
PGR P06401 4/20 0.38
P2RX7 Q99572 1/20 0.38
HTR2A P28223 3/20 0.37
HTR2C P28335 2/20 0.37
KCNH2 Q12809 2/20 0.37
DRD2 P14416 1/20 0.37
ESR1 P03372 1/20 0.36
ESR2 Q92731 1/20 0.36
FFAR1 O14842 2/20 0.36
FFAR4 Q5NUL3 2/20 0.36
CYP11B1 P15538 1/20 0.34
CYP11B2 P19099 1/20 0.34
SLC6A4 P31645 2/20 0.33
CTSB P07858 1/20 0.32
NR3C1 P04150 1/20 0.32
NR3C2 P08235 1/20 0.32
HSD11B1 P28845 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24484644 0.87 P2RX7 (0.37) RORCPGRP2RX7HTR2AHTR2C
SCHEMBL26081049 0.84 RORC (0.38) RORCPGRP2RX7HTR2AHTR2C
SCHEMBL26081053 0.80 PGR (0.33) PGRNR3C1
SCHEMBL26081072 0.79 KDM4E (0.49) HTR2AHTR2CKCNH2DRD2SLC6A4
SCHEMBL309991 0.73 FFAR1 (0.42) PGRP2RX7HTR2AHTR2CKCNH2
SCHEMBL29413229 0.73 FFAR1 (0.42) PGRP2RX7HTR2AHTR2CKCNH2
SCHEMBL26081245 0.72 LRRK2 (0.35) PGRKCNH2
SCHEMBL7770769 0.71 FFAR1 (0.43) PGRFFAR1FFAR4CYP11B1CYP11B2
SCHEMBL31118218 0.71 KDM4E (0.44) RORCHTR2AHTR2CKCNH2DRD2
SCHEMBL5538330 0.70 FFAR1 (0.40) RORCPGRP2RX7HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312522-A1 CYP46A1 INHIBITORS AND METHODS OF USE THEREOF SAGE THERAPEUTICS, INC. 2023-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312522-A1 CYP46A1 INHIBITORS AND METHODS OF USE THEREOF CYP46A1, CYP26A1, CYP4A22 RORC 317/4885PGR 1360/4885P2RX7 2962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.